Q3 Earnings Highlights: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services Stocks

The testing & diagnostics services cohort delivered a strong Q3 overall, beating revenue consensus by 4.9% and seeing average stock gains of 8.8% post-results; key performers included Guardant Health, which posted $265.2m in revenue (+38.5% YoY, +12.6% beat) and is up 40.6% since reporting, and RadNet, which reported $522.9m (+13.4% YoY, +6.3% beat) with Adjusted EBITDA up 15.2% and 26 bps of margin expansion. Large-cap clinical labs were mixed: Quest reported $2.82bn (+13.2% YoY, +3.3% beat) and raised full-year guidance the most among peers, Labcorp posted $3.56bn (+8.6% YoY) in-line with estimates and underperformed the group, while NeoGenomics grew revenues to $187.8m (+11.9% YoY) but offered the weakest full-year guidance update. The results underscore durable demand and digital/AI tailwinds (personalized medicine, at‑home and rapid tests) but leave profitability exposed to reimbursement pressure, competition from decentralized testing and regulatory scrutiny, with broader 2025 outlooks tempered by potential trade and tax policy shifts.

Analysis

The testing & diagnostics cohort delivered a strong Q3, with group revenues beating analysts’ consensus by 4.9% and average share gains of 8.8% post-results, reflecting persistent demand from routine screenings, diagnostic imaging and growing digital services. The industry narrative in the report highlights secular tailwinds—aging demographics, personalized medicine, AI-driven diagnostics and at-home testing—offset by persistent risks from reimbursement uncertainty, decentralized competition and regulatory scrutiny.

Company results were heterogeneous: Guardant Health led with $265.2m revenue (+38.5% YoY) and a 12.6% beat, driving a 40.6% stock rally to $101.61; RadNet reported $522.9m (+13.4% YoY), a 6.3% beat with Adjusted EBITDA +15.2% and 26bps margin expansion while trading flat at $78.54. Quest posted $2.82bn (+13.2% YoY) with a 3.3% beat and the largest full‑year guidance raise but the stock is down 4.1% at $182.54; Labcorp’s $3.56bn (+8.6% YoY) was in line and underperformed, while NeoGenomics grew to $187.8m (+11.9% YoY) but issued the weakest guidance update.

Implications are that revenue durability and digital/AI growth are being rewarded, yet future outperformance will hinge on guidance execution, reimbursement trends and margin leverage from advanced imaging and digital services; market reactions suggest investors are differentiating by growth quality and guidance revisions. Key monitoring items are further guidance updates, reimbursement commentary, digital revenue traction and any M&A or capacity expansion disclosures.

Key Decisions for Investors

• Consider a selective overweight in Guardant Health for high‑growth exposure given the 38.5% revenue gain and guidance beat, but size positions conservatively given rapid repricing
• Add or hold RadNet for a mix of organic growth ($522.9m, +13.4%) and margin expansion (Adjusted EBITDA +15.2%), while monitoring same‑store sales and joint‑venture scaling
• Avoid initiating new long exposure to Labcorp until management provides clearer positive guidance or reimbursement visibility, given its relative underperformance
• Maintain calibrated exposure to Quest and NeoGenomics—favor Quest for its guidance raise potential despite the post‑report price dip, and require clearer full‑year guidance improvement from NeoGenomics before increasing allocation